Table 3.

Cost-effectiveness and ESRD lifetime incidence results of microalbuminuria screening, by race

	All African Americans					All Non-African Americans
	Costs ($)	QALY	ICER versus Usual ($)	ICER versus Next Most Effective ($)	ESRD Lifetime Incidencea	Costs ($)	QALY	ICER versus Usual ($)	ICER versus Next Most Effective ($)	ESRD Lifetime Incidencea
Usual care	148,200	16.537			82	150,300	18.010			35
Universal (yr)
10	148,400	16.567	9000		79	150,500	18.022	17,000		33
5	148,500	16.571	11,000	24,000	78	150,700	18.025	23,000	54,000	33
2	148,900	16.574	19,000	113,000	78	151,000	18.027	44,000	210,000	33
1	149,400	16.575	33,000	635,000	78	151,700	18.027	81,000	1,571,000	33

^aLifetime incidence of initiating ESRD care per 1000 persons.